Zusammenfassung
Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Antidementiva im allgemeinen Teil und dann für jedes Arzneimittel spezifisch im Präparateteil beschrieben.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
Buoli M, Serati M, Caldiroli A et al (2017) Pharmacological Management of Psychiatric Symptoms in Frontotemporal Dementia: A Systematic Review. J Geriatr Psychiatry Neurol 30(3):162–169
Gomm W, von Holt K, Thomé F et al (2016) Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol 73(4): 410–416
Hefner G, Brueckner A, Hiemke C, Fellgiebel A (2015) Therapeutic drug monitoring for patients with Alzheimer dementia to improve treatment with donepezil. Ther Drug Monit 37(3): 353–361
Lange-Asschenfeldt C (2013) Vaskuläre Faktoren in der Pathogenese der Alzheimer-Krankheit. Nervenarzt 84(6): 732–737
McKeith IG, Boeve BF, Dickson DW et al (2017) Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology 89(1): 88–100
Monsell SE, Kukull WA, Roher AE et al (2015) Characterizing apolipoprotein E ε4 carriers and noncarriers with the clinical diagnosis of mild to moderate Alzheimer dementia and minimal β-amyloid peptide plaques. JAMA Neurol 72(10): 1124–1131
Novak P, Schmidt R, Kontsekova E et al (2017) Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol 16(2): 123–134
Padala PR, Padala KP, Lensing SY et al (2018) Methylphenidate for apathy in community dwelling older veterans with mild Alzheimer’s disease: a double-blind, randomized, placebo-controlled trial. Am J Psychiatry 175(2): 159–168
Relkin NR, Thomas RG, Rissman RA et al (2017) A phase 3 trial of IV immunoglobulin for Alzheimer disease. Neurology 88(18): 1768–1775
Saarelainen L, Tolppanen AM, Koponen M et al (2017) Risk of death associated with new benzodiazepine use among persons with Alzheimer disease: a matched cohort study. Int J Geriatr Psychiatry 33(4): 583–590
Schmidt R, Hofer E, Bouwman FH et al (2015) EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer’s disease. Eur J Neurol 22(6): 889–898
Soininen H, Solomon A, Visser PJ et al (2017) 24-month intervention with a specific multinutrient in people with prodromal Alzheimer’s disease (LipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurol 16(12): 965–975
Sondergaard KB, Weeke P, Wissenberg M et al (2017) Non-steroidal anti-inflammatory drug use is associated with increased risk of out-of-hospital cardiac arrest: a nationwide case-time-control study. Eur Heart J Cardiovasc Pharmacother 3(2): 100–107
Stinton C, McKeith I, Taylor JP, Lafortune L et al (2015) Pharmacological management of Lewy body dementia: a systematic review and meta-analysis. Am J Psychiatry 172(8): 731–742
Tan MS, Yu JT, Tan CC et al (2015) Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis. J Alzheimers Dis 43(2): 589–603
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer-Verlag GmbH Deutschland
About this chapter
Cite this chapter
Lange-Asschenfeldt, C., Benkert, O. (2019). Antidementiva. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-57334-1_6
Download citation
DOI: https://doi.org/10.1007/978-3-662-57334-1_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-57333-4
Online ISBN: 978-3-662-57334-1
eBook Packages: Medicine (German Language)